245 related articles for article (PubMed ID: 22795701)
41. Usefulness of Rapid Desensitization Therapy for Severe Rash Caused by Molecularly Targeted Drugs Used in the Treatment of Non-small-cell Lung Cancer.
Nagase M; Ohshima N; Kawashima M; Ohgiya M; Ikeda M; Morio Y; Tamura A
Intern Med; 2020 Dec; 59(24):3201-3205. PubMed ID: 32788540
[TBL] [Abstract][Full Text] [Related]
42. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype.
Luu M; Boone SL; Patel J; Sullivan P; Rademaker AW; Balagula Y; Lacouture ME
Clin Exp Dermatol; 2011 Oct; 36(7):733-8. PubMed ID: 21689147
[TBL] [Abstract][Full Text] [Related]
43. Photosensitive rash due to the epidermal growth factor receptor inhibitor erlotinib.
Luu M; Lai SE; Patel J; Guitart J; Lacouture ME
Photodermatol Photoimmunol Photomed; 2007 Feb; 23(1):42-5. PubMed ID: 17254038
[TBL] [Abstract][Full Text] [Related]
44. Skin Rash Can Be a Useful Marker for Afatinib Efficacy.
Nasu S; Suzuki H; Shiroyama T; Tanaka A; Iwata K; Ryota N; Ueda Y; Takata SO; Masuhiro K; Morita S; Morishita N; Okamoto N; Hirashima T
Anticancer Res; 2018 Mar; 38(3):1783-1788. PubMed ID: 29491117
[TBL] [Abstract][Full Text] [Related]
45. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
[TBL] [Abstract][Full Text] [Related]
46. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Plasma Metabolites From Patients With Non-Small Cell Lung Cancer by Erlotinib Treatment and Skin Rash.
Lee WK; Myong J; Kwag E; Shin Y; Son JW; Yoo BC; Kim BS; Yoo HS; Choi JJ
Integr Cancer Ther; 2023; 22():15347354231198090. PubMed ID: 37750513
[TBL] [Abstract][Full Text] [Related]
48. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
Peréz-Soler R; Saltz L
J Clin Oncol; 2005 Aug; 23(22):5235-46. PubMed ID: 16051966
[TBL] [Abstract][Full Text] [Related]
49. Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer.
Li J; Peccerillo J; Kaley K; Saif MW
JOP; 2009 May; 10(3):338-40. PubMed ID: 19454833
[TBL] [Abstract][Full Text] [Related]
50. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
Sun W; Li J
Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
[TBL] [Abstract][Full Text] [Related]
51. Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.
Saif MW; Merikas I; Tsimboukis S; Syrigos K
JOP; 2008 May; 9(3):267-74. PubMed ID: 18469438
[TBL] [Abstract][Full Text] [Related]
52. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.
Basse C; Chabanol H; Bonte PE; Fromantin I; Girard N
Lung Cancer; 2022 Nov; 173():116-123. PubMed ID: 36198244
[TBL] [Abstract][Full Text] [Related]
53. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21.
Ding K; Pater J; Whitehead M; Seymour L; Shepherd FA
Contemp Clin Trials; 2008 Jul; 29(4):527-36. PubMed ID: 18280222
[TBL] [Abstract][Full Text] [Related]
54. Folliculitis-perifolliculitis related to erlotinib therapy spares previously irradiated skin.
Acharya J; Lyon C; Bottomley DM
J Am Acad Dermatol; 2009 Jan; 60(1):154-7. PubMed ID: 19103369
[TBL] [Abstract][Full Text] [Related]
55. Effect of low-dose aspirin for skin rash associated with erlotinib therapy in patients with lung cancer.
Kanazawa S; Yamaguchi K; Kinoshita Y; Siomi K; Tujimoto M; Hanayama K; Sasada S; Hirashima T; Imamura F; Nomura S
Platelets; 2009 Feb; 20(1):70-1. PubMed ID: 19172526
[No Abstract] [Full Text] [Related]
56. Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): report of a case and review of the literature.
Voulgaris E; Pentheroudakis G; Vassou A; Pavlidis N
Lung Cancer; 2009 May; 64(2):247-9. PubMed ID: 19070399
[TBL] [Abstract][Full Text] [Related]
57. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
Jia Y; Lacouture ME; Su X; Wu S
J Support Oncol; 2009; 7(6):211-7. PubMed ID: 20380328
[TBL] [Abstract][Full Text] [Related]
58. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.
Petrelli F; Borgonovo K; Barni S
Target Oncol; 2013 Sep; 8(3):173-181. PubMed ID: 23321777
[TBL] [Abstract][Full Text] [Related]
59. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash.
Vaubel J; Livingstone E; Schadendorf D; Zimmer L
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1685-9. PubMed ID: 24422792
[TBL] [Abstract][Full Text] [Related]
60. Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
McKibbin T; Zhao W; Tagen M; Daw NC; Furman WL; McGregor LM; Geyer JR; Allen JW; Stewart CF
Eur J Cancer; 2010 Jul; 46(11):2045-51. PubMed ID: 20621735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
